Drug Trial Radar · NCT06181370
Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
143
Actual
Start
Dec 1, 2023
Primary completion
Apr 29, 2026
Study completion Apr 29, 2026
Sponsor
- Lead sponsor
- Agomab Spain S.L.Industry
- Sponsor type
- Industry
- First posted
- Dec 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety, tolerability PK and PD of inhaled AGMB-477 compared with placebo in healthy participants and participants with IPF. This is an integrated phase 1, single center, 3-part, double-blind, randomized, placebo-controlled SAD (Part A) and MAD (Part B) study in healthy participants and multiple dose study in IPF participants (Part C). Safety, tolerability PK and PD will be assessed following single ascending, multiple ascending and multiple dosing of AGMB-447 administered via nebulizer in Part A, B and C, respectively.
Conditions
- IPF
Interventions
AGMB-447Drug
AGMB-447 inhaled drug
placeboOther
placebo inhaled drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: From Screening Through Study Completion, up to 8 Weeks
- Number of participants with abnormal clinical laboratory valuesTime frame: From Screening Through Study Completion, up to 8 Weeks
- Number of participants with abnormal ECG parametersTime frame: From Screening Through Study Completion, up to 8 Weeks
- Number of participants with abnormal vital signsTime frame: From Screening Through Study Completion, up to 8 Weeks
- Number of participants with abnormal physical examsTime frame: From Screening Through Study Completion, up to 8 Weeks
- Number of participants with abnormal spirometry parametersTime frame: From Screening Through Study Completion, up to 8 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medicines Evaluation Unit Ltd. an IQVIA business
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.